An Executive Informational Overview (EIO) is now available on Celsion Corporation, a fully integrated biopharmaceutical company focused on developing cancer therapies for difficult-to-treat forms of cancers. The 68-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Topics: biotech, immunotherapy, cancer, autoimmune, hepatocellular cancer, GEN-1, ovarian cancer, interleukin-12, IL-12, ThermoDox, primary liver cancer, celsion

Crystal Research Associates has issued a 12-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-NASDAQ).

 

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

Crystal Research Associates has issued an 84-page Updated Executive Informational Overview (EIO) on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-NASDAQ), detailing the Company's recent news and developments, anticipated clinical trial and regulatory filing milestones, and financial position. The report is available for download below.

Topics: geovax

Crystal Research Associates has issued an 11-page Quarterly Update on specialty biotech pharmaceutical research and development (R&D) company, FSD Pharma Inc. (HUGE-NASDAQ/HUGE-CSE), detailing the Company's recent news and developments—including its recent permission from the U.S. FDA on June 1, 2020 to submit an Investigational New Drug Application (IND) to use FSD201 to treat COVID-19 (the disease caused by the SARS-CoV-2 virus)—as well as its recent financial position. The report is available for download below.

Topics: Cannabis, fsd pharma, Endocannabinoid System (ECS), Palmitolylethonalamide (PEA), ultramicronized-PEA, fsd, FSD201, medical cannabis, covid19, coronovirus

An Executive Informational Overview (EIO) is now available on CEL-SCI Corporation, a clinical-stage biotechnology company developing immunotherapy technologies to treat cancer, autoimmune, and infectious diseases. The 86-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Topics: biotech, immunotherapy, CEL-SCI, infectious diseases, leaps, cancer, autoimmune, head and neck cancer, squamous cell carcinoma, rheumatoid arthritis, covid19, cervical dysplasia

An Executive Informational Overview (EIO) is now available on StageZero Life Sciences, Ltd (SZLS-TSX), a revenue-generating innovator in the liquid biopsy space, dedicated to the early detection of cancer and multiple disease states. The 72-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Topics: liquid biopsy, blood-based diagnostics, ColonSentry, Sentinel Principle, EarlyCDT®-Lung, BreastSentry, StageZero Life Sciences

An Executive Informational Overview (EIO) is now available on FSD Pharma Inc. (HUGE-NASDAQ/HUGE-CSE), a specialty biotech pharmaceutical company focused on developing FDA-approved synthetic compounds targeting the endocannabinoid system (ECS) of the human body. The 68-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Topics: Cannabis, fsd pharma, Endocannabinoid System (ECS), Palmitolylethonalamide (PEA), Prismic Pharmaceuticals, ultramicronized-PEA, fsd, SciCann Therapeutics, Solarvest BioEnergy Inc., FSD201, medical cannabis, Canntab Therapeutics Ltd, Huge Shops, Aura Health Inc.

An Executive Informational Overview (EIO) is now available on Reliance Global Group, Inc. (RELI-OTC), a diversified holding company investing in real estate and insurance markets. The 48-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Topics: reliance global group, multi-family properties, insurance, insurance carriers, Employee Benefit Solutions, The Referral Depot, reliance global holdings, RELI, insurance agencies, REIT, real estate, U.S. Benefits Alliance, Commercial Solutions of Insurance Agency, Southwestern Montana Insurance Center, Fortman Insurance Agency

Crystal Research Associates has issued an 11-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVXD-OTC), detailing the Company's recent news and developments, anticipated clinical trial and regulatory filing milestones, and financial position. The report is available for download below.

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv

Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-OTC), detailing the Company's recent news and developments, anticipated clinical trial and regulatory filing milestones, and financial position. The report is available for download below.

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv

CVR Medical Corp. announced that it will have its upcoming “Carotid Stenotic Scan (CSS)” device showcased by its manufacturing and strategic partner Canon Virginia, Inc. (CVI), a wholly owned subsidiary of Canon USA, at this week’s Medical Design & Manufacturing West (MD&M) in Anaheim, CA. CVR Medical's CSS is a novel device that uses patented sound wave analysis technology to detect and measure carotid arterial stenosis.

MD&M West is recognized as the main and most comprehensive yearly medical technology and manufacturing expo and conference in North America (https://mdmwest.mddionline.com). From February 5-7, 2019, over 19,000 members of the global medical care and manufacturing community will gather at MD&M West to learn about and exhibit the latest in cutting-edge advancements.

 CVR has partnered with CVI for the manufacturing, supply chain management, logistics, white glove delivery to end user, telephone tech support, and on-site service for the CSS; providing key advantages when CVR scales to meet potential global demand.

With Canon as a recognized leader in imaging technology, CVR gains invaluable exposure and credibility within the industry. Canon’s showcase of the CSS highlights the unique, customized manufacturing of the device, as well as logistics and product support needs. The manufacturing partnership between CVR Medical and Canon, announced in 2017, established the production means through which the CSS will be launched.

****************************************************** 

Learn move about CVR Medical by downloading our Executive Informational Overview (EIO), a 60-page report detailing the Company's business, product development, strategic relationships, market opportunities, competition, financials, risks, and more.

Topics: cvr medical, carotid health, ischemic stroke, occlusion, duplex Doppler ultrasound (DUS), magnetic resonance angiography (MRA), computed tomography angiography (CTA), cerebral angiogram, Henry Ford Hospital, Cleveland Clinic, Canon U.S.A., transient ischemic attack (TIA), medical technology company, Carotid Stenotic Scan (CSS), stenosis, stroke, Thomas Jefferson University Hospital, ENTICES Study, CVM-TSX, CRRVF-OTCQB, atherosclerosis, Army Research Lab

GeoVax announced that it has been nominated for the 2019 ViE (Vaccine Industry Excellence) Awards in three categories. Please use the following link to vote for these special industry awards in the follow categories:

https://www.surveymonkey.co.uk/r/J39ZFW3

• Best Vaccine Technology/Platform
• Best Therapeutic Vaccine
• Best Prophylactic Vaccine
  

GeoVax's development programs are importantly focused on vaccines against HIV as well as Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa), and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy and for therapeutic use in chronic Hepatitis B infections. .

For more information on GeoVax, please read to our most recent Quarterly Update dated November 14, 2018, as well as our Executive Informational Overview (EIO), issued on June 15, 2017 and available for download below.

 

 

*******************************************

Visit our Corporate Profile and Key Points pages

for the latest research on GeoVax Labs, Inc.

*******************************************

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, lassa, lasv

CVR Medical Corp. announced today that it has completed a Food and Drug Administration De Novo Submission for its “Carotid Stenotic Scan (CSS)” device.  A De Novo Submission allows for a company to receive a “not substantially equivalent” risk-based evaluation for any legally marketed device for which there is no prior, comparable classification. 

The Company's CSS, which is a novel device that uses patented sound wave analysis technology to detect and measure carotid arterial stenosis, fits within the criteria of this FDA filing. Due to U.S. government shutdown, the submission will be reviewed by the FDA upon resumption of government activity.
 
CVR's FDA submission marks the culmination of the Company's many years of product development, design, trials, and organizational preparation, and is necessary for any new device entering the market.

****************************************************** 

Learn move about CVR Medical by downloading our Executive Informational Overview (EIO), a 60-page report detailing the Company's business, product development, strategic relationships, market opportunities, competition, financials, risks, and more.

Topics: cvr medical, carotid health, ischemic stroke, occlusion, duplex Doppler ultrasound (DUS), magnetic resonance angiography (MRA), computed tomography angiography (CTA), cerebral angiogram, Henry Ford Hospital, Cleveland Clinic, Canon U.S.A., transient ischemic attack (TIA), medical technology company, Carotid Stenotic Scan (CSS), stenosis, stroke, Thomas Jefferson University Hospital, ENTICES Study, CVM-TSX, CRRVF-OTCQB, atherosclerosis, Army Research Lab

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, lassa, lasv

Crystal Research Associates has released a 17-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-OTC). The report is available for download.

 

 

Snapshot of GeoVax

GeoVax Labs is  developing preventative and therapeutic human vaccines against infectious diseases and cancer. The Company’s patented Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) technology is the foundation for producing non-infectious virus-like particles (VLPs) from the cells of the individual receiving the vaccine. Producing VLPs in a vaccinated individual mimics a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection should it appear, while maintaining the safety characteristics of a replication-defective vector.

GeoVax is focused on developing vaccines against hemorrhagic fever (HF) viruses (Ebola, Sudan, Marburg, and Lassa), Zika virus (ZIKV), malaria, and human immunodeficiency virus (HIV). The Company also has programs to develop a vaccine to treat chronic Hepatitis B virus (HBV) infection and to apply its MVA-VLP technology to cancer immunotherapy (immuno-oncology). Furthermore, GeoVax is collaborating with Emory University to develop a therapeutic vaccine for human papillomavirus (HPV) infection, with a specific focus on head and neck cancer (HNC). GeoVax believes its expertise is complementary to a range of other human diseases for which there is an unmet medical need, and thus, has plans to expand its pipeline.

GeoVax was the winner of the 2018 “Best Biotech” Vaccine Industry Excellence Awards, a finalist for the 2018 “Best Prophylactic Vaccine” Award for its Zika vaccine at the World Vaccine Congress, and a finalist for Pipelines of Promise at Buzz of BIO 2018.

Key Points

• On November 8, 2018, GeoVax issued an overview of its R&D programs as well as reported its financial results for the quarter ended September 30, 2018.

• During the quarter, GeoVax announced that the U.S. Department of Defense (DoD) had awarded the Company a $2.4 million cooperative agreement in support of its novel Lassa Fever (LF) vaccine development program. This followed a Fast-Track Phase I/II SBIR grant award in April 2018 from the National Institutes of Health (NIH) with an expected budget of up to $1.9 million.

• In November 2018, the Company announced the start of a collaboration to develop a therapeutic vaccine for human papillomavirus (HPV) infection. The collaboration is to include preclinical animal testing of GeoVax’s MVA-vectored HPV vaccine candidates in combination with Swiss-based Virometix’ synthetic HPV vaccine candidate.

• The Company further began a collaboration with Vaxeal Holding SA, expanding its cancer vaccine program to include the design, construction, characterization, and animal testing of vaccine candidates using GeoVax’s MVA-VLP vaccine platform with Vaxeal’s proprietary designed genetic sequences. This project is complementary to the ongoing collaboration with ViaMune for co-developing cancer immunotherapies. In parallel, GeoVax is collaborating with the University of Pittsburgh and their Distinguished Professor, Dr. Olja Finn, using combined technologies for abnormal MUC1-expressing tumors.

• The Company’s collaboration with American Gene Technologies International, Inc. (AGT) for use of GeoVax’s vaccine in combination with AGT’s gene therapy to develop a functional cure for HIV is on track to enter a Phase 1 trial sponsored by AGT. AGT expects the trial to begin during the first quarter of 2019. In October 2018, positive results from the HVTN 114 (the Phase 1 trial of GeoVax’s preventive HIV vaccine) were presented at the HIVR4P conference in Madrid, Spain.

• The Company will be represented at the following upcoming conferences: Fourth International Conference on Vaccines Research and Development, Baltimore, Nov. 12-14 and World Vaccine & Immunotherapy Congress, San Diego, Nov. 28-30.

• At September 30, 2018, GeoVax reported cash balances of $511,242 versus $312,727 at December 31, 2017.

 *******************************************

Visit our Corporate Profile and Key Points pages

for the latest research on GeoVax Labs, Inc.

*******************************************

Topics: immunotherapy, Ebola, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, lassa, lasv, Sudan, Marburg